Pabau Engage inbox

Pabau Engage is here: every patient conversation in one inbox.

Learn more
Book a demo Book a demo
☰
Compliance and security

How to open a peptide clinic: 7 steps for licensed practices

Avatar photo Anja Dodevska
Last Updated: November 19, 2026

How to open a peptide clinic: run peptide therapy as a prescribed service inside a licensed practice, led by a licensed prescriber. You also need a licensed 503A or 503B compounding route, a federal status check on each peptide, peptide-specific consent, program pricing and linked records.

Under HHS’s interim enforcement policy of October 28, 2026, HHS won’t act against 503A compounding of six named peptides when strict conditions hold. Those compounded products are still not FDA-approved, and each one still needs a valid patient-specific prescription.

The seven steps below each leave a record that answers a specific rule. We call that chain the peptide service record trail. It’s what you show a board, a pharmacy or a patient who asks why a peptide was given.

Key takeaways

Key takeaways

A peptide clinic is a prescribed service inside a licensed practice, so a licensed prescriber and a patient-specific prescription come first.

Since October 28, 2026, HHS won’t act against 503A compounding of BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 when 10 conditions are met.

FDA’s safety-risk list for compounding, current as of April 22, 2026, still names GHRP-2, GHRP-6, ibutamoren mesylate, ipamorelin acetate and kisspeptin-10.

Practices package peptide programs as a flat monthly fee, a prepaid multi-month program or a membership, and labs are priced inconsistently.

The peptide service record trail ties each launch step to a named record, from the approved prescription to the lot logged against the patient.

Found our content helpful?

Is a peptide clinic a medical practice or a “peptide company”?

A peptide clinic is a licensed medical practice offering a prescribed service. Searches for a “peptide company” usually mean selling research-use-only products, which are not for patient use.

HHS spells out the risk in its own policy. HHS says the interim policy is meant to discourage widespread use of research-use-only peptides from foreign manufacturers. HHS describes those products as a safety risk to US patients.

This guide covers one model only: a licensed prescriber, a licensed pharmacy and a patient record. Sourcing, suppliers and resale are outside its scope.

How to start a peptide clinic in 7 steps

To start a peptide clinic, set up seven things in order: prescribing, status checks, a compounding route, consent, pricing, records and recalls.

The list below is how to start a peptide clinic inside a practice you already run. Each step depends on the one before it.

  1. Decide who prescribes and who supervises.
  2. Check each peptide’s regulatory status before you offer it.
  3. Use a licensed 503A or 503B compounding route.
  4. Write peptide-specific consent and protocols.
  5. Price and package ongoing peptide programs.
  6. Set up the records you must keep.
  7. Bring patients back with recall Workflows.

Step 1: Decide who prescribes and who supervises

A licensed prescriber writes every patient-specific prescription in a peptide clinic. Your state decides who that can be and whether a medical director is required.

Under section 503A, FDA says a drug must be compounded based on a valid patient-specific prescription. That rule is set out in FDA’s compounding law summary, checked November 19, 2026. So the prescriber is the starting point for every order.

Physician, nurse practitioner and physician assistant authority all vary by state, and so do supervision rules. Our guide on who can prescribe peptides covers each role in depth. Where your state requires a medical director, name one before launch.

In Pabau, an all-in-one practice management system, non-prescribers can draft a prescription, but only a prescriber can approve and send it. US e-prescribing runs through DoseSpot, so the approved prescription sits on the patient record from day one.

Step 2: Check each peptide’s regulatory status before you offer it

Before you offer any peptide, check its current federal status. Most peptides marketed to practices are not FDA-approved for the uses promoted.

Two federal documents set the picture on November 19, 2026. The first is the HHS interim policy of October 28, 2026, whose Appendix A names six peptides. HHS won’t take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding them, but only when all 10 conditions hold.

The second is FDA’s safety-risk list of bulk drug substances for compounding, current as of April 22, 2026. That list names five substances practices see marketed as peptides. Ibutamoren mesylate is flagged under both 503A and 503B, for congestive heart failure risk. BPC-157 no longer appears on it.

SubstanceFDA-approved?Current federal statusWhat it means for a 503A orderSource, date checked
BPC-157No (compounded drugs are not FDA-approved)HHS Appendix A, interim policyA 503A pharmacy may compound it only when all 10 policy conditions are met.HHS policy, October 28, 2026; checked November 19, 2026
TB-500No (compounded drugs are not FDA-approved)HHS Appendix A, interim policyA 503A pharmacy may compound it only when all 10 policy conditions are met.HHS policy, October 28, 2026; checked November 19, 2026
EpitalonNo (compounded drugs are not FDA-approved)HHS Appendix A, interim policyA 503A pharmacy may compound it only when all 10 policy conditions are met.HHS policy, October 28, 2026; checked November 19, 2026
KPVNo (compounded drugs are not FDA-approved)HHS Appendix A, interim policyA 503A pharmacy may compound it only when all 10 policy conditions are met.HHS policy, October 28, 2026; checked November 19, 2026
MOTS-cNo (compounded drugs are not FDA-approved)HHS Appendix A, interim policyA 503A pharmacy may compound it only when all 10 policy conditions are met.HHS policy, October 28, 2026; checked November 19, 2026
SemaxNo (compounded drugs are not FDA-approved)HHS Appendix A, interim policyA 503A pharmacy may compound it only when all 10 policy conditions are met.HHS policy, October 28, 2026; checked November 19, 2026
GHRP-2No (compounded drugs are not FDA-approved)FDA safety-risk list, 503B, injectable and nasal routesNot on Appendix A, so the HHS policy gives no cover. Confirm eligibility with the pharmacy and counsel.FDA list, April 22, 2026; checked November 19, 2026
GHRP-6No (compounded drugs are not FDA-approved)FDA safety-risk list, 503BNot on Appendix A, so the HHS policy gives no cover. Confirm eligibility with the pharmacy and counsel.FDA list, April 22, 2026; checked November 19, 2026
Ibutamoren mesylateNo (compounded drugs are not FDA-approved)FDA safety-risk list, 503A and 503BFDA lists it as a significant safety risk under both, citing congestive heart failure, and it is not on Appendix A.FDA list, April 22, 2026; checked November 19, 2026
Ipamorelin acetateNo (compounded drugs are not FDA-approved)FDA safety-risk list, 503BNot on Appendix A, so the HHS policy gives no cover. Confirm eligibility with the pharmacy and counsel.FDA list, April 22, 2026; checked November 19, 2026
Kisspeptin-10No (compounded drugs are not FDA-approved)FDA safety-risk list, 503AFDA lists it as a significant safety risk for 503A compounding, and it is not on Appendix A.FDA list, April 22, 2026; checked November 19, 2026

GLP-1 drugs are FDA-approved prescription drugs for their labeled indications. Treat them as a separate decision, never as interchangeable with a compounded peptide.

HHS says it may revisit the policy if a safety signal or product quality issue arises. Re-check both documents before each launch, then confirm your state’s rules with the state board and counsel, because they differ by state. This guide is not legal advice.

Step 3: Use a licensed 503A or 503B compounding route

Order compounded peptides only through a state-licensed 503A pharmacy filling a patient-specific prescription, or through an FDA-registered 503B outsourcing facility.

FDA says an outsourcing facility must comply with CGMP requirements and is inspected on a risk-based schedule (FDA on outsourcing facilities, checked November 19, 2026). FDA also says a 503B facility may distribute against a patient-specific prescription or a provider’s order, such as office stock. The HHS interim policy addresses 503A compounding only.

Before the first order, the practice confirms these points with the pharmacy:

  • The pharmacy’s state license, or the facility’s FDA registration as an outsourcing facility.
  • That each 503A order is filled against a valid patient-specific prescription.
  • A certificate of analysis (COA) for the bulk substance that lists the original manufacturer’s location, as HHS conditions 3 and 4 require.
  • A lot number and an expiry date on every product you receive.
  • The label statement “This is a compounded drug product. Not for resale.”, which is HHS condition 6.
  • How the pharmacy reports serious adverse events and quality issues to FDA MedWatch, and how it runs recalls.

Keep the COA, lot and expiry with the patient record when the product arrives. That pairing is what lets you trace a recall back to the patients who received the lot.

Peptide consent should state that the product is compounded and not FDA-approved. It should also cover off-label use, monitoring and how to report a reaction.

  • Compounded status: HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.
  • Off-label use, where it applies to the peptide prescribed.
  • The monitoring plan, including labs, follow-up visits and who the patient contacts.
  • How to report an adverse event or a product problem, matching the route on the product labeling under HHS condition 5.

Protocols are your prescriber’s own work. Write down who may prescribe, the review schedule and what pauses a program. This guide gives no dosing.

In Pabau, consent and intake forms go out before the visit. The completed form lands in the patient record rather than sitting as a PDF. Pabau GO, our iOS app for practitioners, supports care-pathway forms and consents, so a patient can sign before arriving.

Step 5: Price and package ongoing peptide programs

Practices price peptide programs in three ways: a flat monthly fee, a prepaid multi-month program, or a membership that buys clinician access.

Four US practices publish peptide program prices on their own websites. The table shows each one as listed on November 19, 2026, at package level only.

PracticeLocationModelPublished price(s)LabsSource
Perfect B Aesthetic MedicineDoral, FLPrepaid program priced by number of peptides and one-month cyclesOne peptide: $445 (1 cycle), $1,135 (3), $1,845 (6). Four peptides: $1,295, $3,305, $5,325. A $150 consult deposit is credited to treatment.Optional, priced separatelyPerfect B price page, checked November 19, 2026
Ageless PensacolaPensacola, FLTiered membershipFoundations $79 per visit, no monthly commitment. Transform $149/month and Transcend $229/month, each with a 3-month minimum.Billed separately by the labAgeless Pensacola programs, checked November 19, 2026
Patients MedicalNew York, NYLongevity membership for physician time, with peptides priced separately$300, $600 or $1,250 per month. A standalone evaluation is $600. Peptides vary by compound and quantity.Core labs billed separatelyPatients Medical pricing, checked November 19, 2026
360 MDAustin, TXFlat monthly membership, no commitment$250/month, with an initial month of $400.Baseline labs included360 MD peptide membership, checked November 19, 2026

Two patterns stand out on these pages. Commitment is rewarded, through a prepaid cycle or a minimum term. Labs are the least consistent line item: included, optional, or billed by the lab.

For tier design, our guide to longevity membership pricing shows how practices structure membership levels.

Pabau handles recurring memberships and treatment packages for hormone, GLP-1 and longevity programs. Pabau’s membership tools bill weekly, monthly or yearly, and a perk can cover a service, a category or wallet credit with rollover. The till also sells 2–12 month installment plans through Stripe, so a prepaid program doesn’t need one lump payment.

Step 6: Set up the records you must keep

The peptide service record trail is seven records, from the approved prescription to the lot number logged against the patient, each answering a named rule.

Keep all seven on one patient record, so an inspector, a pharmacy or a covering clinician sees the whole chain. Each item below names the rule it satisfies.

  • Prescription approved by a licensed prescriber — the section 503A patient-specific prescription requirement, which is also HHS condition 10.
  • A dated status check for each peptide offered — HHS Appendix A and FDA’s safety-risk list.
  • The COA, lot and expiry from the pharmacy — HHS conditions 3 and 4.
  • Signed consent with the adverse-event reporting route — HHS condition 5 and the compounded, not-FDA-approved disclosure.
  • Signed program or membership terms — your own cancellation and refund policy.
  • Lot and expiry recorded against the patient and the appointment — recall traceability back to the pharmacy lot.
  • Follow-up notes, labs, adverse events and product complaints — the monitoring plan in the consent, with MedWatch as the reporting route.

The chart below lines up each launch step with the record it leaves and the rule behind it.

The peptide service record trail
Step 6 carries the most weight, because the lot logged against each patient is what makes a recall traceable. Sources: HHS interim policy (October 28, 2026) and FDA’s safety-risk list (current as of April 22, 2026).

A batch number kept on a paper log, away from the patient record, is the weakest link in the trail.

In Pabau, stock carries a batch number and an expiry date, and the lot is recorded against the patient and the appointment. Practices can switch on Labs, which lets them order Quest tests from the patient record with their own Quest login. Quest results import automatically.

Labcorp orders are placed in Labcorp Link, and results sync back automatically. A biomarker-over-time chart then sits on the patient record, next to the consent and prescription.

Step 7: Bring patients back with recall Workflows

Book each peptide patient’s review before the current cycle ends, so monitoring happens before any reorder.

In Pabau, recall Workflows use 90-day and 6-month templates to send SMS, email or WhatsApp. Pabau’s recall Workflows skip patients who already have a booking, so nobody gets chased twice. SMS uses usage-based credits, so a text-heavy recall plan adds to the monthly bill.

Track three numbers from launch: follow-up visits completed, reorders that had a review first, and adverse-event reports logged. If reorders outrun reviews, pause new starts until the reviews catch up.

Should you add peptide therapy to your practice or open a standalone clinic?

If you already run a licensed practice, add peptide therapy to your practice as a new service line. The license, prescriber, records and patients already exist.

Four delivery models show up across practices offering peptides:

  • Existing practice add-on: uses your current license, prescriber and patient base, with the fewest new moving parts.
  • Standalone peptide clinic: a new entity, so ownership and corporate-practice rules apply that differ by state. Confirm the structure with counsel.
  • Telehealth: the prescriber must meet licensure rules in the patient’s state. Telehealth in Pabau uses 1 credit per minute per staff member.
  • Hybrid: an in-person first visit with telehealth follow-ups, which suits monitoring-heavy programs.

Whichever model you pick, run it on one system rather than a second stack. Pabau’s longevity clinic software keeps peptide, hormone and longevity programs on the same patient record. Pabau bills insurance too, with electronic claims in the US, UK and Australia, and policies, authorizations and superbills in Canada.

Practices adding peptides often run IV therapy as well. Our guide on opening an IV therapy clinic covers that launch. Where peptides sit inside a wider longevity program, our guide on how to build a longevity clinic walks through oversight, lab partners and membership design.

What can a peptide clinic not claim or sell?

A peptide clinic should make no healing, anti-aging, performance or outcome claims, and should never supply research-use-only products to patients.

The FTC’s Health Products Compliance Guidance (December 2022, checked November 19, 2026) says health benefit claims for drugs need competent and reliable scientific evidence. The FTC also says an honest testimonial does not replace that evidence.

  • No healing, anti-aging, performance or outcome claims in ads, scripts or social posts.
  • No research-use-only product for patient use, and no resale of compounded product.
  • No brand names of approved drugs to describe a compounded product.
  • “FDA-approved” only where it is true, and never for a compounded peptide.
  • No patient testimonials standing in for evidence.

Give the front desk approved wording, and a rule to pass every clinical question to the prescriber.

Pabau runs booking, charting, consent forms, payments and memberships for practices that offer aesthetics, hormone therapy, weight loss and longevity care in one system. For a peptide service, the prescription, consent, lot number and recall reminder all sit on the same patient record.

Pabau handles self-pay, memberships and insurance billing in one system, in the US, UK and Australia. Every Pabau plan includes the core features, and add-ons enhance the experience. Credits for SMS, 2FA, telehealth and Pabau Scribe, our AI scribe, are usage-based, so check Pabau’s pricing page for current rates.

Each new practice starts with structured onboarding before it goes live. Pabau is rated 4.8 on G2 and 4.7 on Capterra.

Comparing systems first? Our roundup of software for peptide clinics sets the main options side by side. If peptides sit inside a wider longevity program, see our pick of the best longevity clinic software.

Keep every peptide record on one file

Pabau keeps the approved prescription, signed consent, lot and expiry, and recall Workflows on one patient record. Each peptide decision leaves a record your team can find in seconds.

Pabau clinic management dashboard

Conclusion

The peptide service record trail is what makes a peptide service defensible. When a board, a pharmacy or a patient asks why a peptide was given, the answer should already be on the record.

Federal status will keep moving. The HHS policy is interim and FDA’s list changes, so re-check both before each new peptide goes live.

The trade-off is a slower start. A practice that builds the records first may launch with fewer peptides, but it can show its work on every one.

Book a demo to see how Pabau keeps prescriptions, consent, lot numbers and recalls for your peptide service on one patient record.

Continue your research

Continue your research

Choosing a system for peptide therapy? Best peptide therapy clinic software compares the platforms practices use to run peptide programs.

Designing membership tiers? Longevity clinic membership pricing shows how practices structure and price membership levels.

Building a functional medicine service line? How to start a functional medicine practice walks through the launch steps for that model.

Frequently asked questions

Do you need a medical license to open a peptide clinic?

Yes, in practice. Anyone working out how to start a peptide clinic needs a licensed prescriber and a valid patient-specific prescription for each patient. Ownership and supervision rules vary, so check with your state medical board and counsel.

Can a med spa offer peptide therapy?

Yes. A med spa can add peptide therapy to its practice as a prescribed service when a licensed prescriber orders each product. Medical director rules for med spas differ by state, so check your state board first.

Is BPC-157 legal to compound in 2026?

Since October 28, 2026, HHS has said it won’t take enforcement action against 503A compounding of BPC-157 when all 10 interim-policy conditions are met. BPC-157 is still not FDA-approved, and state boards may set their own limits.

Does a peptide clinic need a medical director?

A peptide clinic needs a medical director where its state requires one. Requirements differ on physical presence, supervision and delegation, and every prescription still needs a licensed prescriber.

Found our content helpful?
Avatar photo
Anja Dodevska
Content Writer

Anja Dodevska writes about healthcare, dermatology, and the day-to-day realities of running a medical practice for Pabau. She enjoys breaking down complex topics into clear, accessible content and has a soft spot for the often-overlooked aspects of clinic life. When she's not writing, she's exploring cafes, walking her dog, or spending time with friends and family.
×